All research papers

Prostate-specific membrane antigen in malignant brain tumors: vascular heterogeneity, imaging promise, and therapeutic challenges

External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy

Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC

Deep learning for automatic detection of prostatectomy in CT images of prostate cancer patients.

First-in-human evaluation of 225Ac-PSMA-Trillium™ (BAY 3563254; 225Ac felivotide mopaxetan) in metastatic castration-resistant prostate cancer: the phase 1 PAnTHA study

Large Calyceal Diverticulum Mimicking a Solid Renal Mass in a Patient Undergoing 68Ga-DOTATATE PET/CT.

An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C-IV non-squamous NSCLC.

The evolving role of radiotherapy in oligometastatic pancreatic cancer: from palliation to disease-modifying multidisciplinary integration.

Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer.

The value of fibroblast activation protein inhibitor-based radionuclide theranostics in sarcoma: a systematic review.

¹⁸F‑FAPI‑04 PET/CT imaging of fibroblast activating protein reveals myocardial injury beyond cancer staging.

Exposure of unmonitored workers to ionizing radiation due to portable X-ray machine use and area dose mapping in an emergency department in King Abdulaziz Medical City, Jeddah.

Automated workflow for target volume propagation in online adaptive magnetic resonance guided radiotherapy for lung lesions using foundation models.

One-step flow synthesis and [⁶⁸Ga]Ga radiolabelling of metal phenolic network nanoparticles for in vivo PET tracking.

The role of particle therapy in the treatment of locally recurrent rectal cancer: a systematic review.

Peptide Receptor Radionucleotide Therapy for Unresectable Paediatric Head and Neck Paraganglioma in Aotearoa New Zealand.

Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges

Salvage treatment strategies for recurrence after radical prostatectomy: Current status, challenges, and future directions

Metal artifact reduction for 3 T MRI-only prostate radiotherapy in patients with hip prostheses: impact on target definition, synthetic CT generation, dose calculation, and fiducial marker identification.

Nanoparticle-Based Strategies to Enhance PSMA-Targeted Radioligand Therapy: A Review of the Delivery, Co-Formulation, and Combination Landscape Surrounding Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto)

Upright Immobilization for Proton Therapy: A Critical Review and Single-Institution Experience.

Corrigendum to 'Explainability-informed benchmarking of two deep learning models for organ-at-risk segmentation in MR-guided adaptive radiotherapy' [Journal of Medical Imaging and Radiation Sciences 57/3 (2026) 102200].

Learning-enhanced hybrid planar-SPECT dosimetry for voxel-level Monte Carlo dose estimation in radionuclide therapy.

Three Cases of Merkel Cell Carcinoma Treated With Lutetium-177 Oxodotreotide.

Effective treatment of carcinoid syndrome with peptide receptor radionuclide therapy.

Real-World Outcomes of Lenvatinib in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Multicentre Retrospective Study.

Dual-Tracer ⁶⁸Ga-PSMA and ⁶⁸Ga-DOTATATE PET/CT in Advanced Prostate Cancer: Persistent PSMA Expression Despite Clinically Suspected Treatment-Emergent Neuroendocrine Differentiation.

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

[⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study.

Targeted Alpha Therapy as a Multiscale Design Problem: From Radioactive Decay to Therapeutic Outcome.

Correlation of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT Uptake Parameters with PASS and GAPP Scores in Pheochromocytoma.

Experimental radiotherapy with the gastrin-releasing peptide receptor (GRPR) antagonist [177Lu]Lu-AU-SAR-M1 in a prostate cancer murine model using reduced-frequency dosing

Single-fraction stereotactic radiosurgery vs. hypofractionated stereotactic radiotherapy for resected brain metastases: a systematic review and meta-analysis of comparative studies.

Site-specific performance and complexity-dependent risk assessment of patient-specific quality assurance using a 2D array detector in CyberKnife radiosurgery.

Predicting unfavorable response to initial radioactive iodine therapy in differentiated thyroid cancer: an explainable machine learning and survival analysis approach.

Sequential 18F-FDG and 68Ga-FAPI-04 PET/CT in Early Peritoneal Recurrence of Signet-Ring-Component Rectal Adenocarcinoma.

FAP-targeted gold nanocluster-mediated radioligand therapy in combination with TGF-βRI inhibition for tumor therapy.

Comparison of ⁶⁸ga fapi pet/ct and ¹⁸f-fdg pet/ct in primary staging of breast cancer.

Topology-preserved transformer-based CBCT-CT registration via normalized gradient field guidance for nasopharyngeal carcinoma.

Discordant ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT Findings Before Radionuclide Therapy in Small Cell Lung Cancer.

How reliable is deep inspiration breath hold at CT simulation? Clinical impact of surface-guided breathing training in breast cancer radiotherapy.

Correlation of [¹⁸F]SiTATE-PET-tracer with somatostatin receptor expression in meningiomas: an exploratory ex vivo histological pilot study.

Imaging Features That Predict Indeterminate Bone Lesion Outcomes on ¹⁸F-DCFPyL PSMA PET/CT Scan: A Multicenter Cohort of 42 Biopsy-Proven Lesions.

Laying the groundwork for future health economic evaluation of [¹⁸F]PSMA PET/CT in guiding treatment decisions for metastatic castration-resistant prostate cancer patients.

68Ga-FAPI-04 PET/CT has high diagnostic efficacy in Tg-positive and Tg-negative differentiated thyroid cancer.

Isotope Harvesting at the Facility for Rare Isotope Beams: Progress and Current Status.

Recombinant human thyrotropin reducing insulin resistance in patients with differentiated thyroid cancer.

Intermediate risk thyroid cancer management: physician survey.

Fibroblast activation protein-α in liver fibrosis and hepatocarcinogenesis: Stromal remodeling, molecular imaging, and theranostic targeting.

Brain metastasis: Opportunities for novel therapies.

Discrepancy between Collapsed Cone and Monte Carlo algorithms in lung inhomogeneity correction.

Optimizing the therapeutic ratio of PSMA-PET-guided para-aortic radiotherapy for prostate cancer: A systematic review and structured quantitative synthesis.

Solitary Flat Bone Metastasis of Follicular Thyroid Carcinoma: Complete Molecular and Partial Structural Response After 2 ¹³¹I Therapies.

Radiomics on ¹⁷⁷Lu-DOTATATE Posttreatment Scans: Feasibility, Preprocessing Optimization, and Planar-SPECT Comparison.

A Prospective, Single-Center, Single-Arm, Exploratory Study of ¹⁷⁷Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.

Strategic driving of the cancer-immunity cycle in HCC: roles of immune, molecular-targeted, and locoregional therapies.

MRI distortion correction produces geometrically relevant shifts in cisternal trigeminal nerve localization: implications for gamma knife radiosurgery.

Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II).

Role of ¹⁸F-PSMA PET/MRI in Prostate Cancer Recurrence After Prostatectomy.

Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.